NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-OD-17-026 from the NIH Guide for Grants and Contracts
Notice NOT-OD-17-003 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-16-504 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites an application from the Program Director/Principal Investigator (PD/PI) of the current Data Coordinating Center (DCC) for The Environmental Determinants of Diabetes in the Young (TEDDY) study, an ongoing epidemiological study. This DCC has been involved in study design and data and biosample acquisition and management since the inception of the TEDDY Consortium. This FOA provides support for the TEDDY DCC to continue to follow TEDDY children, allowing collaborators to conduct further studies in the measurement and analysis of immune markers using samples from TEDDY subjects.
Notice NOT-OD-17-023 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-17-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for the Developmental Centers for Interdisciplinary Research in Benign Urology Program (P20). The intent of this Program is to further advance research in benign urology by building research teams and facilitating resources generation and sharing. The research teams should be composed of individuals with complementary expertise who propose to either develop innovative resources (Resource Development Projects) or new research projects (Scientific Research Projects) that utilize integrative approaches to address questions relevant to benign urological diseases or disorders. Resources developed by the Resource Development Projects will be shared upon validation while resources developed within the Scientific Research Projects will be shared at the end or termination of the award, as appropriate and consistent with the program goal of further advancing research. Each Developmental Center is centered on a single Project and must contain an Administrative Core and an Educational Enrichment Program. As part of the efforts of the Division of Kidney, Urologic and Hematologic Diseases (DKUH) to expand and enhance benign urology research, the Developmental Centers Program will work in partnership with the George M. OBrien Urology Cooperative Research Centers Program (U54) and the Multidisciplinary K12 Urologic Research (KURe) Career Development Program.
Funding Opportunity RFA-HD-18-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications that use novel approaches for the development of safe, real-time, non-invasive (or minimally invasive), in vivo methods to assess the development and function of the human placenta across pregnancy.
Funding Opportunity RFA-HD-18-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications that use novel approaches for the development of safe, real-time, non-invasive (or minimally invasive), in vivo methods to assess the development and function of the human placenta across pregnancy.
Notice NOT-HD-16-036 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DE-18-002 from the NIH Guide for Grants and Contracts. The objective of the NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) is to provide longer-term support to NIDCR-funded investigators, who are in their mid-career stage, and have outstanding records of research productivity, mentorship and professional service to the research community. It is expected that the SOAR Award will propel the investigator along this career trajectory and allow him/her to embark on ambitious longer-term projects of extraordinary potential within the mission of NIDCR. This award supports research projects for up to eight years.
Funding Opportunity RFA-DK-17-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications for projects to develop strategies to target the human pancreatic environment in-vivo to deliver cell-based therapeutics, regulatory molecules or gene constructs that can protect or replenish the functional beta cell mass, or to develop synthetic sentinel biomarkers to safely monitor beta cell stress or disease initiation prior to the appearance of autoantibodies in individuals at risk of developing Type 1 Diabetes (T1D). Successful applicants will join the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase functional human beta cell mass in vivo through the controlled manipulation of beta cell replication, islet cell plasticity, or the reprogramming of pancreatic non-beta cells into beta-like cells. CTAR is part of the Human Islet Research Network (HIRN).
Notice NOT-DK-17-003 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-17-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement solicits applications for collaborative research projects that will enhance the goals of the Human Islet Research Network (HIRN; www.hirnetwork.org). The HIRN is a collaborative program consisting of multiple related but distinct research consortia focused around two common goals: increasing our understanding of how human beta cells are lost in Type 1 Diabetes (T1D), and finding innovative strategies to protect or replace functional beta cell mass in diabetic patients. Applicants to this FOA will be expected to lend unique perspectives and novel approaches to the network, and will be expected to pursue experiments that will be consistent with HIRN's continuing emphasis on studies that elucidate key aspects of human biology and physiology.
Funding Opportunity PAR-17-080 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIMH R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs.
Funding Opportunity PAR-17-081 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIMH R25 program is to support educational activities that will help recruit and retain individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences.
Funding Opportunity PAR-17-082 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIMH R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical mental health-related research needs.
Funding Opportunity RFA-MH-17-614 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the mechanism and change in functional or clinical effects. Ultimately, this FOA is intended to support a sufficiently-powered efficacy trial to determine the intervention's potential for significant clinical benefit.
Funding Opportunity RFA-MH-17-612 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot research consistent with NIMH's priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. Applications should provide resources for evaluating the feasibility, tolerability, acceptability and safety of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve service delivery, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale intervention trial (e.g., comparative effectiveness study, practical trial) or large-scale services study.
Funding Opportunity RFA-MH-17-610 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions.
Funding Opportunity RFA-MH-17-602 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g. schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder, etc.). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused interventions are appropriate for this FOA. This R33 FOA supports single phased clinical trial awards. Applicants proposing high risk projects are encouraged to apply to the companion FOA, RFA-MH-17-600.
Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01)
Funding Opportunity RFA-MH-17-608 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. Applicants interested in submitting multi-site effectiveness trials (e.g., to answer primary effectiveness questions and key questions regarding moderators/mechanisms, to ensure geographic and demographic diversity)are directed to RFA-MH-17-610 "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01)".